Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S G Ellis

Showing results (161-170 of 222) with videos related to

Pageof 23
Sort By:
Circulation|November 1, 1989
Recurrent ischemia without warning. Analysis of risk factors for in-hospital ischemic events following successful thrombolysis with intravenous tissue plasminogen activatorS G Ellis, E J Topol, B S George, et al.
Journal of the American College of Cardiology|March 1, 1993
Lack of impact of early catheterization and fibrin specificity on bleeding complications after thrombolytic therapy. The TAMI Study GroupT C Wall, R M Califf, S G Ellis, et al.
American Heart Journal|March 7, 2001
Outcome of acute ST-segment elevation myocardial infarction in patients with prior coronary artery bypass surgery receiving thrombolytic therapyM Labinaz, M H Sketch, S G Ellis, et al.
American Heart Journal|February 26, 2000
Predictors of death and reinfarction at 30 days after primary angioplasty: the GUSTO IIb and RAPPORT trialsS J Brener, S G Ellis, S K Sapp, et al.
American Heart Journal|February 1, 1990
Relationship between antecedent angina pectoris and short-term prognosis after thrombolytic therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study GroupD W Muller, E J Topol, R M Califf, et al.
Journal of the American College of Cardiology|March 1, 1992
Accelerated plasminogen activator dose regimens for coronary thrombolysis. The TAMI-7 Study GroupT C Wall, R M Califf, B S George, et al.
Coronary Artery Disease|February 1, 1993
Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein IIb/IIIa in patients undergoing elective coronary angioplastyS G Ellis, J E Tcheng, F I Navetta, et al.
Lancet (London, England)|April 9, 1994
Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC InvestigatorsE J Topol, R M Califf, H F Weisman, et al.
Circulation|January 1, 1991
Clinical experience with the Palmaz-Schatz coronary stent. Initial results of a multicenter studyR A Schatz, D S Baim, M Leon, et al.
The American Journal of Cardiology|December 11, 1991
Causes and correlates of death after unsupported coronary angioplasty: implications for use of angioplasty and advanced support techniques in high-risk settingsS G Ellis, R K Myler, S B King, et al.
Pageof 23

Showing results (161-170 of 222) with videos related to

Sort By:
Pageof 23
Circulation|November 1, 1989
Recurrent ischemia without warning. Analysis of risk factors for in-hospital ischemic events following successful thrombolysis with intravenous tissue plasminogen activatorS G Ellis, E J Topol, B S George, et al.
Journal of the American College of Cardiology|March 1, 1993
Lack of impact of early catheterization and fibrin specificity on bleeding complications after thrombolytic therapy. The TAMI Study GroupT C Wall, R M Califf, S G Ellis, et al.
American Heart Journal|March 7, 2001
Outcome of acute ST-segment elevation myocardial infarction in patients with prior coronary artery bypass surgery receiving thrombolytic therapyM Labinaz, M H Sketch, S G Ellis, et al.
American Heart Journal|February 26, 2000
Predictors of death and reinfarction at 30 days after primary angioplasty: the GUSTO IIb and RAPPORT trialsS J Brener, S G Ellis, S K Sapp, et al.
American Heart Journal|February 1, 1990
Relationship between antecedent angina pectoris and short-term prognosis after thrombolytic therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study GroupD W Muller, E J Topol, R M Califf, et al.
Journal of the American College of Cardiology|March 1, 1992
Accelerated plasminogen activator dose regimens for coronary thrombolysis. The TAMI-7 Study GroupT C Wall, R M Califf, B S George, et al.
Coronary Artery Disease|February 1, 1993
Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein IIb/IIIa in patients undergoing elective coronary angioplastyS G Ellis, J E Tcheng, F I Navetta, et al.
Lancet (London, England)|April 9, 1994
Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC InvestigatorsE J Topol, R M Califf, H F Weisman, et al.
Circulation|January 1, 1991
Clinical experience with the Palmaz-Schatz coronary stent. Initial results of a multicenter studyR A Schatz, D S Baim, M Leon, et al.
The American Journal of Cardiology|December 11, 1991
Causes and correlates of death after unsupported coronary angioplasty: implications for use of angioplasty and advanced support techniques in high-risk settingsS G Ellis, R K Myler, S B King, et al.
Pageof 23